BiotechTube

SCY-078 + Fluconazole + Echinocandin

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Invasive

Conditions

Candidiasis, Invasive, Candidemia

Trial Timeline

Aug 3, 2022 → Dec 16, 2025

NCT ID
NCT05178862

About SCY-078 + Fluconazole + Echinocandin

SCY-078 + Fluconazole + Echinocandin is a phase 3 stage product being developed by Scynexis for Candidiasis, Invasive. The current trial status is terminated. This product is registered under clinical trial identifier NCT05178862. Target conditions include Candidiasis, Invasive, Candidemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05178862Phase 3Terminated

Competing Products

20 competing products in Candidiasis, Invasive

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
33
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Fluconazole + MicafunginAstellas PharmaApproved
85
Micafungin + CaspofunginAstellas PharmaPhase 3
77
Micafungin + FluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPhase 2
52
micafungin + caspofunginAstellas PharmaPhase 3
77
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
77
FK463Astellas PharmaPhase 2
52
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
77
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
L-743,872MerckPre-clinical
23
CaspofunginMerckPhase 2
52
L-743,872MerckPhase 2
52
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
52
Caspofungin acetate + PlaceboMerckPhase 2
52
Caspofungin + Normal SalineMerckApproved
85

Other Products from Scynexis

IbrexafungerpPhase 3
69
SCY-078Phase 3
69
IbrexafungerpPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletPhase 3
69
Ibrexafungerp + PlaceboPhase 3
69